Navigation Links
New Multiple Sclerosis Therapy Promising in Early Trial
Date:11/1/2011

TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.

The errant behavior of the cells in question -- known as "B cells" -- is viewed as key to the development of this chronic and disabling nervous system disease, commonly called MS.

The new therapy's potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.

But initial indications suggest that the new antibody drug, called ocrelizumab, successfully targets these renegade cells with hopeful results: a significant reduction in disease-related inflammatory brain lesions.

"Our findings show that ocrelizumab rapidly suppresses inflammatory activity," noted the study authors, led by Dr. Ludwig Kappos from the University Hospital, Basel, Switzerland, in a journal news release.

Describing the targeting of B cells as an "innovative therapeutic approach," Kappos and his colleagues reported that in testing among 218 patients, the drug's impact on lesions was "rapid and pronounced." What's more, to date the treatment appears to be safe.

The study authors noted that MS is a progressively debilitating disease that attacks an individual's central nervous system, disrupting the normal brain, spinal cord and optic nerve function.

A classic characteristic of the disease is inflammation, which takes the form of brain lesions.

The immune system's T cells have long been implicated in disease progression, but the notion that B cells may also play a major role is relatively new.

With this new potential target in mind, researchers configured ocrelizumab to specifically focus on a protein (CD20) found on the surface of certain B cells.

To test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.

The patients were divided into four groups, treated with: a low dose of ocrelizumab (600 milligrams); a high dose of ocrelizumab (2,000 mg); a well-known MS inflammation treatment known as "intramuscular interferon beta-1a"; or a sugar pill (placebo). After 24 weeks, some of the doses were adjusted.

The result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.

The number of active lesions had dropped 89 percent more among the 600-mg group compared with those getting a placebo. Similarly, those in the 2,000-mg group experienced a 96 percent bigger drop in lesions. What's more, relapse rates were much lower among those taking the new drug, in contrast to those taking a placebo.

The investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.

That said, Dr. Moses Rodriguez, a professor of neurology and immunology at the Mayo Clinic in Rochester, Minn., disputed the premise that ocrelizumab is shaping up as anything new and innovative.

"In fact, there's nothing novel about this at all," he said. "There is another drug, called rituximab, that's been in early trials for MS for years. And all this new drug is attempting to do is replicate the same that rituximab already does. And I see no major advantage of this drug versus that older drug. It's not better or worse. It's the same," Rodriguez noted.

"So bottom-line, I would not sell this as a major breakthrough in MS," cautioned Rodriguez. "It's not."

Funding for the study was provided by F. Hoffmann-La Roche and Biogen Idec. Inc.

More information

For more on multiple sclerosis, visit the U.S. National Library of Medicine.

-- Alan Mozes

SOURCES: The Lancet, news release, Oct. 31, 2011; Moses Rodriguez, M.D., professor, neurology and immunology, Mayo Clinic, Rochester, Minn.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Migraine Tied to Raised Multiple Sclerosis Risk
2. Exercise helps protect brain of multiple sclerosis patients
3. Fitness Boosts Brain Power in Multiple Sclerosis Patients
4. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
5. Multiple sclerosis, Italian researchers discover a possible onset mechanism for the disease
6. Multiple Medalist Kristina Groves Matches Hain Celestials $5,000 Donation to Right to Play
7. Complex New Guidelines From Multiple Organizations Confuses Men About Prostate Cancer Screening
8. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
9. MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010
10. 'Miracles For MSA' Proclaims March as Multiple System Atrophy Awareness Month
11. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Multiple Sclerosis Therapy Promising in Early Trial
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
(Date:8/16/2017)... Lake Orion, Rochester, Michigan (PRWEB) , ... August ... ... now offer treatment options to patients suffering from chronic pelvic pain. In ... treatment of various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during ...
(Date:8/16/2017)... ... 16, 2017 , ... With low back pain afflicting 8 of 10 Americans at some point ... – upper back pain. But this equally vexing condition stems from a variety of causes ... Liu, MD, PhD , founder and president of Atlantic Spine Center. , Nestled between ...
(Date:8/15/2017)... ... 15, 2017 , ... Western University of Health Sciences President ... forward in bold new directions while using its foundational values of humanism and ... the traditional opening of the academic year, on August 12, 2017 at Fairplex ...
(Date:8/15/2017)... ... August 15, 2017 , ... An ... who fell into a coma and died after receiving silicone injections for buttock ... performed in the alleged perpetrator’s apartment after the victim was fetched from a ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve ... his tenure, Paul has served us in multiple leadership roles ... Pharmacy in Jun. 2015 and has provided decisive, strategic leadership ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
Breaking Medicine Technology: